课题基金 / 基金详情

A PHASE II STUDY TO EVALUATE THE IMMUNOGENICITY AND SAFETY OF QUADRIVALENT: HIV

A PHASE II STUDY TO EVALUATE THE IMMUNOGENICITY AND SAFETY OF QUADRIVALENT: HIV
评估四价 HIV 免疫原性和安全性的 II 期研究
批准号：
7951591
负责人：
MARGRIT CARLSON
金额：
$2.06万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
项目状态：
已结题
起止时间：
2009-04-01 至 2009-11-30
来源：
https://reporter.nih.gov/project-details/7951591
关键词：
AntibodiesCD4 Lymphocyte CountClinical ResearchComputer Retrieval of Information on Scientific Projects DatabaseDevelopmentFundingGrantHIVHuman PapillomavirusInstitutionPhase II Clinical TrialsRecombinant VaccinesResearchResearch PersonnelResourcesSafetySeriesSourceUnited States National Institutes of Healthimmunogenicity

项目摘要

项目成果

MARGRIT CARLSON的其他基金

相关文献

中文摘要
翻译
这个子项目是众多研究子项目之一
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To determine the development of titers in each CD4+ cell count stratum of antibodies to HPV 6, 11, 16, and 18 above a level of type-specific seropositivity after the quadrivalent HPV recombinant vaccine series
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
FLUCONAZOLE AS CHRONIC SUPPRESSIVE VS EPISODIC THERAPY IN HIV PATIENT
COMPARISON OF THE VIROLOGIC EFFECACY OF NELFINAVIR AND/OR DMP-266 IN COMBINATION
ANTIVIRAL ACTIVITY OF T 20 ADMINISTERED TO HIV 1 POSITIVE ADULTS
TRIAL OF EFAVIRENZ OR NELFINAVIR & INDINAVIR IN HIV INFECTED SUBJECTS